Accordingly, administration of IL-17A had effects similar to psoriasis-like inflammation on neurobehavioral and NFκB/p38MAPK pathways, while blockade of both NFκB and p38MAPK reduced IL-17A levels associated with depression-like behavior. The gene discussed is IL17A; the disease is major depressive disorder.